key: cord-0876939-kku2ey9s authors: Fukuyama, Hidehiro; Shinnakasu, Ryo; Kurosaki, Tomohiro title: Influenza vaccination strategies targeting the hemagglutinin stem region date: 2020-06-16 journal: Immunol Rev DOI: 10.1111/imr.12887 sha: 0ec55175a9bd9f874c7f757f6e03c3fa5f9b8142 doc_id: 876939 cord_uid: kku2ey9s Influenza is one of the best examples of highly mutable viruses that are able to escape immune surveillance. Indeed, in response to influenza seasonal infection or vaccination, the majority of the induced antibodies are strain‐specific. Current vaccine against the seasonal strains with the strategy of surveillance‐prediction‐vaccine does not cover an unmet virus strain leading to pandemic. Recently, antibodies targeting conserved epitopes on the hemagglutinin (HA) protein have been identified, albeit rarely, and they often showed broad protection. These antibody discoveries have brought the feasibility to develop a universal vaccine. Most of these antibodies bind the HA stem domain and accumulate in the memory B cell compartment. Broadly reactive stem‐biased memory responses were induced by infection with antigenically divergent influenza strains and were able to eradicate these viruses, together indicating the importance of generating memory B cells expressing high‐quality anti‐stem antibodies. Here, we emphasize recent progress in our understanding of how such memory B cells can be generated and discuss how these advances may be relevant to the quest for a universal influenza vaccine. Each year approximately one billion cases of influenza virus infection are reported, of which 3-5 million are severe cases and 290-650 thousand lead to deaths. 1 Effectiveness Estimates, https://www.cdc.gov/flu/vacci nes-work/ past-seaso ns-estim ates.html). Note that these seasonal vaccines will provide little or no protection against unpredictable pandemic influenza viruses such as H5N1 and H7N9. Multiple immune reactions contribute to protection in influenza infection. Among them, antibodies alone can adequately protect from infection, while T cell-mediated reactions seem to play an important role in recovery. 6, 7 Influenza vaccines induce serum antibodies against two major glycoproteins on the surface of the virus, HA and NA. Antibodies against the globular head of HA are detected by the HI (HA inhibition) assay, and their titers boosted by vaccination are generally correlated with protection. 8 Interestingly, Clements et al 9 reported that serum titers detected by the NA inhibition assay are correlated with protection against virus challenge or illness after use of the inactivated vaccine. To date, the influenza vaccine is designed to target the HA protein. The ultimate goal is to develop a universal vaccine against both a broad range of seasonal influenza virus strains and pandemic strains. In this regard, in 1993, Okuno et al 10 first isolated a broadly neutralizing antibody (bnAb) against group 1 influenza viruses. This finding demonstrated the feasibility of developing a universal vaccine. This mAb, called C179, recognizes a unique conformation formed by the HA1 and HA2 domains of the stem region of HA, which is evolutionally well-conserved among many strains 11 (Figure 2 ). Since 2008, many groups have succeeded in isolating human monoclonal antibodies able to neutralize a broad spectrum of influenza virus strains. 12 Among them, some bnAbs even recognize both group 1 and group 2 viruses. Despite molecular identification for broadly reactive antibodies as mentioned above, it has not been clear which type of cells are majorly responsible for protection against re-infection of variant influenza viruses in vivo. In this regard, we summarize recent progress to show the importance of memory B cells. Then, we discuss the potential ways to induce memory B cells carrying broadly reactive antibodies in breadth and affinity. Influenza viruses acquire seasonal mutations, which results in the evolution of viral envelope proteins (primary targets of antibodymediated protection) comprising variable regions (head region) and conserved regions (stem region) ( Figure 2 ); the stem region is essential for virus survival. In order to protect the conserved domains from antibody surveillance, viruses are thought to employ at least two strategies. First, the conserved domains are weakly immunogenic or immunologically subdominant in contrast to the immunologically dominant head domains, 13 for instance, because the precursor frequency of B cells with germline ancestor antibodies recognizing the conserved regions is inherently low in humans [14] [15] [16] and mice (unpublished data). Even so, there are still significant numbers of such B cells; however, the conserved regions also provide steric hindrance to prevent antibody access. 17 Second, the structural mimicry of host self-antigens by epitopes within the conserved domains moderates immunogenicity through immunological tolerance, thereby mitigating the generation of broadly reactive antibodies toward the conserved epitopes. Indeed, previous studies revealed that the majority of unmutated germline ancestors of broadly reactive antibodies against HIV 18 or influenza viruses 17, 19 are autoreactive or polyreactive. Hence, as discussed later, targeting to block these virus survival strategies would be one possible approach when considering vaccine development. Among the two humoral memory compartments derived from GC, long-lived plasma cells (LLPCs) and memory B cells, LLPCs secrete antibodies with the highest affinities for the primary infection virus; therefore, they are mostly directed toward the dominant HA head F I G U R E 1 Phylogenetic tree of major influenza A virus HA subtypes. Sixteen HA subtypes are separated into group 1 (blue) and group 2 (red) based on phylogenetic relatedness. Nine hundred seventy-five segments of the HA sequences were aligned, and the phylogenetic tree was generated using Influenza Research Database website 80 followed by iTOL. 81 Then In the case of HIV vaccination, iterative entry of memory B cells into GC reactions is thought to be required for the generation of more broadly neutralizing antibodies to various HIV variants. Indeed, the known antibodies with this capability have a remarkably large number of mutations generated by SHM. Hence, it will be important to know whether conventional influenza vaccination induces reentry of pre-existing, particularly broadly reactive, memory B cells into GCs and, if not, to understand why this does not take place. To this end, two human studies analyzed B cell repertoires upon conventional influenza vaccination. Since they could not directly analyze GC reactions, these studies had to employ blood samples. 34 Upon vaccination, pre-existing memory B cells to the F I G U R E 3 Two humoral memory compartments, LLPCs and memory B cells. A, Immunodominant head-specific LLPCs and sub-immunodominant stem-specific memory B cells. The head region of HA contains epitopes that are immunodominant during infection or vaccination, while the stem region is subdominant. Antibodies against the head region have relatively higher affinity than those against the stem region and are usually strain-specific. The immunodominant head region-specific B cells differentiate into LLPCs. In contrast, the subdominant stem region-specific B cells become memory B cells that are potentially cross-reactive with other virus strains. B, Three mechanisms of generating stemspecific memory B cells. As described in Figure 3A , stem-specific B cells enter the memory B cell pool (Scenario 1). Once individuals are infected or vaccinated, antibodies against the head region are dominantly induced and continue to be produced. Those preexisting head-specific antibodies mask the HA head epitope in a subsequent challenge so that unmasked stem-specific B cells are able to respond and become memory cells (Scenario 2). Since several HIV and influenza bnAbs likely bind to self-antigens, those Abs are believed to be derived from a B cell repertoire with low affinity for self-antigens. Eventually, those B cells undergo SHM that triggers an override to recognize the stem region of HA. Those activated B cells can enter the memory pool (Scenario 3) stem region expanded, but these expanded B cells underwent little additional SHM. In contrast, naive or freshly generated memory B cells specific for H7N9 head epitopes evolved and maturated over several months. Collectively, these three human studies indicate that, upon vaccination with the current influenza vaccine, pre-existing memory B cells, particularly anti-stem memory B cells, can be activated, but it is difficult for them to enter the GC and undergo further diversification. A mouse study has reached the same conclusion and provided more mechanistic insights into why pre-existing memory B cells cannot be recruited into GCs. Their experiments used a prime-boost mouse model (influenza PR8 infection followed by vaccination with homologous PR8 HA proteins). Upon secondary vaccination, recall GCs were mostly derived from new naive B cells, but not from pre-existing memory B cells. 35 So, why then do pre-existing memory B cells, upon conventional vaccination, behave in a seemingly non-beneficial way for us ( Figure 4) ? First, previous transfer experiments demonstrate that memory B cells defined by surface IgG expression or by markers of more mature memory phenotype are prone to differentiate into plasmablasts, 36 rather than entering into GCs. Such types of memory B cells prone to plasmablasts might be preferentially activated, probably because of their higher affinity for the secondary antigen. Second, it is generally thought that memory B cells have higher affinity and are present at higher precursor frequencies than naive B cells specific for the same antigen. However, given that several different memory subsets coexist, only one of which has the propensity to enter GCs, the actual number of generated memory B cells capable of entering the GC might be small. In contrast, the number of naive B cells with sufficient affinity to enter a primary GC reaction is large. Hence, the precursor frequency of memory B cells capable of reentering GCs might be very small. Finally, in contrast to transfer experiments into naive mice, in non-transfer conditions, negative feedback by pre-existing and/or de novo generated antibodies might operate, which could limit GC entry of clones specific for epitopes targeted by these antibodies. It will be important to elucidate which mechanisms are predominantly responsible for the inability of memory B cells to reenter the GC. It is likely that an effective vaccination approach for influenza will depend on several rounds of vaccination and the generation of mem- 47 Sequential immunization with these chimeric HAs predominantly induced production of stem-specific antibodies. The strategies described above did demonstrate crossprotection from virus challenges but not cross-neutralization. In 2015, protein structure-based design and screenings provided two headless HA recombinant proteins that could induce cross-protection. 48, 49 One of them even showed the induction of broadly neutralizing antibodies using the pre-clinical adjuvant matrix M. 49 These F I G U R E 5 Two major functions of antibodies for protection. Antibodies directly target viruses and prevent their entry into the host cell by blocking the virus-host cell interaction (1) or membrane fusion (2) . Recent studies also demonstrated that some antibodies can inhibit the virus neuraminidase activity (3) critical for virus budding. 82 In addition, after virus infection, viral envelope proteins expressed on the infected cell surface are opsonized by antibodies. Effector cells, for example, NK cells, recognize these antibody-opsonized infected cells via their Fc receptors and then eliminate the infected cells by antibody-dependent cellular cytotoxicity structure studies clearly showed the importance of conformation of the HA to fully induce broadly neutralizing and protective antibodies. Surprisingly, many of these stem-targeted bnAbs shared a common conformational epitope with C179. 11 Targeting this small region of the conformational epitope is a challenge for designing a stable vaccine antigen. For immunogen design, two concerns exist. First, choosing an antigen epitope enabling induction of autoantibody had better be avoided. There exists a trade-off between autoreactivity and breadth of the cross-reactive antibody. Various BCR transgenic mouse studies of bnAbs against HIV demonstrated that bnAbs are autoreactive and designated to be inactivated by central tolerance. [50] [51] [52] [53] [54] [55] In fact, Bajic et al 19 showed biochemically that 6 influenza bnAbs are poly-and self-reactive. Our recent investigation of one bnAb revealed that the bnAb-bearing B cell is self-reactive and targeted for receptor editing in vivo (unpublished results). Given these observations, we need to design an antigen able to induce antibodies that broadly neutralize virus entry and at the same time cannot be a target for tolerance. In the case of HIV, the b12 antibody seems to be in this category. 54 Second, as mentioned above in the mouse prime-boost model, only a minority of memory-derived clones reenter the GC, demonstrating that the constriction of the relatively divergent primary memory B cell repertoire takes place by boosting. 35 Therefore, in order to be efficiently targeted by sequential vaccination, an epitope should be rendered dominant from the beginning. Thus, efforts to target epitopes of interest by engineering high-affinity germline antibody-targeting immunogens 56 or occluding normally immunodominant regions 57 are needed. As discussed above, at least three factors can be considered to block For instance, we would design an antigen consisting of either a "no man(antibody)'s land" epitope in the HA protein or a de novo synthetic antigen proficient for vaccine efficacy. Apart from manipulating memory B cells, fueling TFH (T follicular helper) cells in GC in vaccine development is also important. TFH cells control antigen-specific GC responses quantitatively and qualitatively. Cognitive interaction between TFH cells and B cells through TCR and MHCII in GC facilitates proliferation of antigen-specific B cells and introduction of SHMs in B cells for affinity maturation. 58 Several human studies showed that the numbers of peripheral memory TFH cells are correlated with the amount of HIV bnAbs. 59, 60 Furthermore, an experiment using the macaque animal model demonstrated that GC TFH cells are associated with bnAbs. 61 Antigen-specific TFH cells are required for GC expansion, and several adjuvants are reported to be able to expand TFH cells. These include squalene-based adjuvants such as MF59, 62, 63 Alum + TLR7 ligand, 63 and other TLR ligands, [64] [65] [66] [67] [68] [69] [70] and glucopyranosyl lipid adjuvant-stable emulsion, GLA-SE. 71 A reasonable goal for the development of a universal influenza vaccine has been proposed: "A vaccine with ≥75% protection against symptomatic disease caused by group 1 and group 2 influenza A viruses lasting ≥12 months in all populations". 74 Estimates of global seasonal influenza-associated respiratory mortality: a modelling study Influenza cost and cost-effectiveness studies globally-a review A virus obtained from influenza patients Results of immunization by means of active virus of human influenza 1 Current knowledge of influenza vaccine The systemic and mucosal immune response of humans to influenza A virus Cell-mediated protection in influenza infection The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin Broadly neutralizing antiviral antibodies Defining B cell immunodominance to viruses Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses Targeting B cell responses in universal influenza vaccine design Structural and genetic basis for development of broadly neutralizing influenza antibodies Immune history profoundly affects broadly protective B cell responses to influenza Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies Requirement for memory B-cell activation in protection from heterologous influenza virus reinfection Time elapsed between Zika and dengue virus infections affects antibody and T cell responses Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis Age Dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans Clonal selection and learning in the antibody system Germinal centers: programmed for affinity maturation and antibody diversification Visualizing antibody affinity maturation in germinal centers Regulated selection of germinal-center cells into the memory B cell compartment A Temporal switch in the germinal center determines differential output of memory B and plasma cells Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity Low CD21 expression defines a population of recent germinal center graduates primed for plasma cell differentiation Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting Memory B cells Influenza and antibody-dependent cellular cytotoxicity Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection A Neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins Highly conserved protective epitopes on influenza B viruses Antibody recognition of a highly conserved influenza virus epitope A highly conserved neutralizing epitope on group 2 influenza A viruses Recurring and adaptable binding motifs in broadly neutralizing antibodies to influenza virus are encoded on the D3-9 segment of the Ig gene The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen Hemagglutininstem nanoparticles generate heterosubtypic influenza protection Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10 Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10 B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice Germline-encoded affinity for cognate antigen enables vaccine amplification of a human broadly neutralizing response against influenza virus Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies Follicular helper cell biology: a decade of discovery and diseases Human circulating PD-1(+)CXCR3(-)CXCR5(+) memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies Quality and quantity of T-FH cells are critical for broad antibody development in SHIVAD8 infection MF59 mediates Its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake IL-18 and subcapsular lymph node macrophages are essential for enhanced B cell responses with TLR4 agonist Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses Toll-like receptor 9 signaling acts on multiple elements of the germinal center to enhance antibody responses Combinatorial delivery of dual and triple TLR agonists via polymeric pathogen-like particles synergistically enhances innate and adaptive immune responses Toll-like receptors: the Swiss army knife of immunity and vaccine development IL-6 production by TLR-activated APC broadly enhances aged cognate CD4 helper and B cell antibody responses in vivo Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRbeta clonotypes IL-12 blocks Tfh cell differentiation during salmonella infection, thereby contributing to germinal center suppression Repurposing the Psoriasis Drug Oxarol to an ointment adjuvant for the influenza vaccine The Pathway to a universal influenza vaccine Advances in the development of influenza virus vaccines Is a universal influenza vaccine feasible? Ther Adv Vaccines Immunother Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood Interactive Tree Of Life (iTOL) v4: recent updates and new developments e410. How to cite this article: Fukuyama H, Shinnakasu R, Kurosaki T. Influenza vaccination strategies targeting the hemagglutinin stem region The authors acknowledge P. Burrows for critical reading. This work was supported by grants to HF, RS, and TK. from the Ministry of Education, Culture, Sports, Science and Technology in Japan, grants to RS from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and grants to TK and HF from the Secom Science and Technology Foundation.